RSV G protein specific antibodies
US10017562B2 · kind B2 · utility
0Cited by
0References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2017 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Jun 30, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/135
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The invention further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.